

Atty. Dkt. No. 039386-0239

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Withdrawn) A purified polypeptide comprising an amino acid sequence selected from the group consisting of:
 - a) the amino acid sequences of SEQ ID NO: 2,
 - b) a naturally-occurring amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 2,
 - c) a biologically active fragment of the polypeptide having the amino acid sequence of SEQ ID NO: 2, and
 - d) an immunogenic fragment of the polypeptide having the amino acid sequence of SEQ ID NO: 2.
2. (Withdrawn) An isolated polypeptide of claim 1, having the amino acid sequence of SEQ ID NO: 2.
- 3.-23. (Canceled)
24. (Withdrawn) A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:
 - a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
 - b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.
- 25.-27. (Canceled)

Atty. Dkt. No. 039386-0239

28. (Currently Amended) An isolated antibody which specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of:

- the amino acid sequence of a polypeptide comprising SEQ ID NO: 2[.];
- a naturally occurring a polypeptide comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 2, wherein said polypeptide inhibits phospholipase activity; and
- an immunogenic fragment of epitope comprising at least 10 contiguous amino acids of SEQ ID NO:2, wherein said polypeptide generates an antibody that specifically binds to SEQ ID NO:2.

29. (Canceled)

30. (Original) The antibody of claim 28, wherein said antibody is:

- a chimeric antibody,
- a single chain antibody,
- a Fab fragment,
- a F(ab')₂ fragment, or
- a humanized antibody.

31. (Currently Amended) A composition comprising an the antibody of claim 28 and an acceptable excipient.

32. (Withdrawn) A method of diagnosing a condition or disease associated with the expression of GIPL in a subject, comprising administering to said subject an effective amount of the composition of claim 31.

33. (Cancelled)

Atty. Dkt. No. 039386-0239

34. (Withdrawn) A method of diagnosing a condition or disease associated with the expression of GIPL in a subject, comprising administering to said subject an effective amount of the composition of claim 33.
35. (Currently Amended) A method of preparing a polyclonal an antibody with the specificity of the antibody of claim 28 comprising:
 - a) immunizing an animal with a polypeptide having the amino-acid sequence of SEQ ID NO: 2, or an immunogenic fragment thereof, under conditions to elicit an antibody response; and
 - b) isolating antibodies from said animal; and
 - c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having the amino acid sequence of SEQ ID NO: 2,
, wherein said isolated antibodies specifically bind to a polypeptide selected from the group consisting of:
 - i) a polypeptide comprising SEQ ID NO: 2;
 - ii) a polypeptide comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2, wherein said polypeptide inhibits phospholipase activity; and
 - iii) an epitope comprising at least 10 contiguous amino acids of SEQ ID NO: 2.
36. (Currently amended) An A polyclonal antibody produced by the method of claim 35.
37. (Original) A composition comprising the antibody of claim 36 and a suitable carrier.
38. (Currently Amended) A method of making a monoclonal an antibody with the specificity of the antibody of claim 28 comprising:

Atty. Dkt. No. 039386-0239

- a) immunizing an animal with a polypeptide ~~having the amino acid sequence of SEQ ID NO: 2, or an immunogenic fragment thereof, under conditions to elicit an antibody response;~~
- b) ~~isolating antibody producing cells from the animal;~~
- c) ~~fusing the antibody producing cells from the immunized animal of step (a) with immortalized cells to form monoclonal antibody-producing hybridoma cells; and~~
- d) ~~culturing the hybridoma cells; and~~
- e) ~~isolating from the culture monoclonal antibody which binds specifically to a polypeptide having the amino acid sequence of SEQ ID NO: 2.~~
- c) isolating antibodies from the hybridoma cells of step (b), wherein said isolated antibodies specifically bind to a polypeptide selected from the group consisting of:
 - i) a polypeptide comprising SEQ ID NO: 2;
 - ii) a polypeptide comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2, wherein said polypeptide inhibits phospholipase activity; and
 - iii) an epitope comprising at least 10 contiguous amino acids of SEQ ID NO: 2.

39. (Currently Amended) A monoclonal antibody produced by ~~a~~ the method of claim 38.

40. (Original) A composition comprising the antibody of claim 39 and a suitable carrier.

41.-44. (Canceled)

45. (New) The antibody of claim 28, wherein said antibody specifically binds to a polypeptide comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 2, wherein said polypeptide inhibits phospholipase activity.

Atty. Dkt. No. 039386-0239

46. (New) The antibody of claim 28, wherein said antibody comprises a reporter molecule.

47. (New) A diagnostic test for a condition or disease associated with the expression of GIPL comprising:

- a) combining a biological sample with an isolated antibody which specifically binds to a polypeptide selected from the group consisting of:
 - i) a polypeptide comprising SEQ ID NO: 2;
 - ii) a polypeptide comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2, wherein said polypeptide inhibits phospholipase activity; and
 - iii) an epitope comprising at least 10 contiguous amino acids of SEQ ID NO: 2; and
- b) determining the presence of binding between said antibody and GIPL, wherein the presence of said binding correlates with the presence of GIPL in said biological sample;

wherein said condition or disease associated with the expression of GIPL is selected from the group consisting of viral infection, bacterial infection, fungal infection, autoimmune response, hereditary condition, cancerous condition, glomerulonephritis, pregnancy, rheumatoid arthritis, osteoarthritis, scleroderma, insect bite or sting, and snake bite or sting.

48. (New) A method for detecting a polypeptide comprising SEQ ID NO: 2 in a sample, comprising:

- a) incubating said sample with an isolated antibody which specifically binds to a polypeptide selected from the group consisting of:
 - i) a polypeptide comprising SEQ ID NO: 2;

Atty. Dkt. No. 039386-0239

- ii) a polypeptide comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2, wherein said polypeptide inhibits phospholipase activity; and
- iii) an epitope comprising at least 10 contiguous amino acids of SEQ ID NO: 2; and

- b) detecting the presence of binding between said antibody and a polypeptide comprising SEQ ID NO: 2, wherein the presence of said binding correlates with the presence of said polypeptide in said sample.

49. (New) A method of purifying a polypeptide comprising SEQ ID NO: 2 from a sample, comprising:

- a) incubating said sample with an isolated antibody which specifically binds to a polypeptide selected from the group consisting of:
 - i) a polypeptide comprising SEQ ID NO: 2;
 - ii) a polypeptide comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2, wherein said polypeptide inhibits phospholipase activity; and
 - iii) an epitope comprising at least 10 contiguous amino acids of SEQ ID NO: 2; and
- b) separating the antibody from the polypeptide comprising SEQ ID NO: 2 in said sample.